Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy
Abstract
BACKGROUND: Severe neutropenia (grade ≥3) is a major adverse event in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving triplet therapy. The purpose of this study was to investigate the influence of lead-in androgen-deprivation therapy (ADT) on the incidence of grade ≥3 neutropenia.
METHODS: This post hoc analysis of the ARASENS phase 3 trial compared patients with and without lead-in ADT. Inverse probability of treatment weighting (IPTW) balanced baseline characteristics. The primary endpoint was grade ≥3 neutropenia incidence. External validation utilized multicenter real-world data.
FINDINGS: The ARASENS cohort included 847 patients (lead-in ADT, n = 748; no lead-in, n = 99). The lead-in-ADT group showed a lower incidence of grade ≥3 neutropenia during the first docetaxel cycle than the no-lead-in-ADT group (11.36% vs. 17.17%, p = 0.0328; adjusted odds ratio [OR]: 0.50, 95% confidence interval [CI]: 0.26-0.95). Overall survival showed no significant difference. Real-world validation (N = 202; lead-in ADT, n = 136; no lead-in ADT, n = 66) confirmed this lower incidence with lead-in ADT (11.03% vs. 37.88%, p < 0.0001; adjusted OR: 0.19, 95% CI: 0.09-0.42).
CONCLUSIONS: Patients receiving lead-in ADT experienced a lower incidence of grade ≥3 neutropenia during the first docetaxel cycle than those not receiving lead-in ADT. This finding may contribute to improved prevention strategies for grade ≥3 neutropenia.
FUNDING: This study was funded by the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 847 participants or records.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.